Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Yibin Li; Weixi Guo; Bin Jiang; Chengkun Han; Feng Ye; Jingxun Wu

doi:10.3389/fonc.2022.863771

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Front Oncol. 2022 Aug 9:12:863771. doi: 10.3389/fonc.2022.863771. eCollection 2022.

Authors

Yibin Li¹, Weixi Guo², Bin Jiang³, Chengkun Han⁴, Feng Ye¹, Jingxun Wu¹

Affiliations

¹ Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
² Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China.
³ Department of Neurology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
⁴ Department of Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, China.

Abstract

Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR.

Keywords: Dacomitinib (PubMed CID: 11511120); EGFR; L747P mutation; brain metastasis; lung cancer.

Publication types

Case Reports